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Case report
A young woman presented 
with generalised tense blis­
ters, which had developed 2 
days earlier (Fig. 1). There 
appeared to be no mucosal involve ment, 
and the distribution mainly involved the 
face, trunk and extremities. There had been 
no previous drug exposure. She had neither 
clinical signs of autoimmune disease nor 
evidence of sepsis. Given the abrupt onset 
and clinical scenario, a skin punch biopsy 
was performed and a tentative diagnosis of 
linear IgA bullous dermatosis (LABD) was 
made.
Dapsone, an immunomodulatory sulfone 
that has been supported for use in LABD 
by case reports and clinical observation, 
was administered to the patient. An 
adjunctive oral corticosteroid was added to 
accelerate resolution. The biopsy fin dings 
were supportive of a subepidermal blistering 
disorder, such as LABD. Subepidermal sect­
ions demonstrated fibrin, neutrophils and 
focal eosinophils. Perivascular infiltrate of 
lymphocytes was identified in the dermis. 
Immunofluorescence was unfortunately 
unavailable. After just 5 days of therapy, 
dramatic improvement was noted (Fig. 2), 
and she continued to improve.
LABD remains an uncommon condition, 
with incidence rates reported to be ranging 
from <0.5 to 2.3 cases per million individuals 
per year.
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A young woman presented with generalised tense blisters. A tentative diagnosis of linear IgA bullous dermatosis (LABD) was supported by 
biopsy findings. Dramatic improvement was noted after 5 days of treatment with dapsone. 
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Fig. 1. Multiple blistering lesions evident on 
admission.
Fig. 2. Clinical response noted at day 5 of therapy. 
The blistering lesions had resolved, leaving 
hypopigmented macular areas.
